BiolineRx Poised for Record Jump After Deal With Genoscience

BioLineRx Ltd. (BLRX) was headed for the biggest surge on record after the Israeli company that develops therapeutic pharmaceutical drugs signed a deal with France’s Genoscience to develop and commercialize a treatment.

The shares surged 33 percent, the most on a closing basis since February 2007 when Bloomberg started tracking them, to 1.598 shekels at 3:57 p.m. in Tel Aviv.

BioLineRx signed an “exclusive license agreement” with Genoscience for its BL-8020 oral treatment for Hepatitis C, it said in a filing with the Tel Aviv Stock Exchange.

To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at ssolomon22@bloomberg.net

To contact the editor responsible for this story: Claudia Maedler at cmaedler@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.